johnson & johnson announces its last phase 3 covid-19 vaccine trial ensemble is fully enrolled.
johnson & johnson announces its last phase 3 covid-19 vaccine trial ensemble is fully enrolled.
111 the large-scale, pivotal, multi-country phase 3 trial (ensemble) of the investigational janssen covid-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants.", "phase 3 trial (ensemble) of investigational janssen covid-19 single-dose vaccine candidate is fully enrolled with about 45,000 participants.", "learn more our company johnson & johnson initiates pivotal global phase 3 clinical trial of janssens covid-19 vaccine candidate johnson & johnson initiates pivotal global phase 3 clinical trial of janssens covid-19 vaccine candidate first participants dosed in phase 3 trial (ensemble) evaluating safety and efficacy of janssens covid-19 vaccine candidate, jnj-78436735, also known as ad26.cov2.s new brunswick, n.j., september 23, 2020  johnson & johnson (nyse: jnj) (the company) today announced the launch of its large-scale, pivotal, multi- country phase 3 trial (ensemble) for its covid-19 vaccine candidate, jnj-78436735, being developed by its janssen pharmaceutical companies."


































)